The Impact of Age on the Efficacy of 13-valent Pneumococcal Conjugate Vaccine in Elderly

DSpace/Manakin Repository

The Impact of Age on the Efficacy of 13-valent Pneumococcal Conjugate Vaccine in Elderly
 
van Werkhoven, Cornelis H.; Huijts, Susanne M; Bolkenbaas, M; Grobbee, Diederick E; Bonten, Marc J M
(2015) Clinical Infectious Diseases, volume 61, issue 12, pp. 1835 - 1838
(Article)
Abstract
In a post hoc analysis of the Community-Acquired Pneumonia (CAP) immunization Trial in Adults the model-predicted 13-valent pneumococcal conjugate vaccine efficacy for preventing vaccine-type specific CAP and Invasive Pneumococcal Disease declined from 65% to 40% for subjects being 65 and 75 year olds at the time of vaccination, respectively.
Download/Full Text
The full text of this publication is not available.
Version on publisher website for UU-students and staff
Version on publisher website
 
Keywords: pneumococcal conjugate vaccine, community-acquired pneumonia, invasive pneumococcal disease, vaccine efficacy, immunosenescence, Journal Article, Randomized Controlled Trial
DOI: https://doi.org/10.1093/cid/civ686
ISSN: 1058-4838
Publisher: Oxford University Press
Note: © The Author 2015. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.
(Peer reviewed)